Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases.
第一作者:
Manyi,Xu
第一单位:
The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310000, China.
作者:
主题词
人类(Humans);吲哚类(Indoles);喹啉类(Quinolines);男(雄)性(Male);小细胞肺癌(Small Cell Lung Carcinoma);女(雌)性(Female);脑肿瘤(Brain Neoplasms);中年人(Middle Aged);肺肿瘤(Lung Neoplasms);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);回顾性研究(Retrospective Studies);成年人(Adult);老年人, 80以上(Aged, 80 and over);Kaplan-Meiers评估(Kaplan-Meier Estimate)
DOI
10.1007/s12094-024-03390-y
PMID
38363527
发布时间
2024-06-27
- 浏览0

Clinical & translational oncology
1687-1695页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文